Open access
Open access
Powered by Google Translator Translator

Internal Medicine

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs.

12 Aug, 2021 | 09:02h | UTC

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs – World Health Organization

Commentary:

WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch

Related:

A giant trial of COVID-19 treatments organized by the WHO is restarting. Here are the drugs it’s betting on.

WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

 

Commentary on Twitter (thread – click for more)

 

Video: Frequently Asked COVID-19 Vaccine Questions – August 2021 Update.

12 Aug, 2021 | 08:59h | UTC

Frequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA

 

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

12 Aug, 2021 | 09:05h | UTC

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Commentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Related:

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

 

Guideline: Diagnosis and management of cutaneous lupus erythematosus – Therapy, risk factors and other special topics.

12 Aug, 2021 | 08:55h | UTC

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics – Journal of German Society of Dermatology

 

2021 guidelines for management of venous thromboembolism in Latin America.

12 Aug, 2021 | 08:56h | UTC

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America – Blood Advances

 

Review: Diagnosis of uncomplicated and complicated appendicitis in adults.

12 Aug, 2021 | 08:45h | UTC

Diagnosis of Uncomplicated and Complicated Appendicitis in Adults – Scandinavian Journal of Surgery

 

Adverse events and hospital-acquired conditions associated with potential low-value care in Medicare beneficiaries.

12 Aug, 2021 | 08:42h | UTC

Adverse Events and Hospital-Acquired Conditions Associated With Potential Low-Value Care in Medicare Beneficiaries – JAMA Health Forum

Commentary: Hospital overuse linked to thousands of adverse events each year – Lown Institute

 

Commentary on Twitter (thread – click for more)

 

Brief review: Nails in systemic disease.

12 Aug, 2021 | 08:40h | UTC

Nails in systemic disease – Clinical Medicine Journal

 

Brief review: Immunobullous disease.

12 Aug, 2021 | 08:37h | UTC

Immunobullous disease – Clinical Medicine Journal

 

Psoriasis: a brief overview.

12 Aug, 2021 | 08:39h | UTC

Psoriasis: a brief overview – Clinical Medicine Journal

 

Brief review: Advances in atopic dermatitis.

12 Aug, 2021 | 08:32h | UTC

Advances in atopic dermatitis – Clinical Medicine Journal

 

Cutaneous manifestations of infections: an update for general physicians.

12 Aug, 2021 | 08:36h | UTC

Cutaneous manifestations of infections: an update for general physicians – Clinical Medicine Journal

 

M-A: Asymptomatic SARS-CoV-2 infection – “we estimate that the percentage of infections that never developed clinical symptoms, and thus were truly asymptomatic, was 35.1%”.

11 Aug, 2021 | 08:49h | UTC

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis – Proceedings of the National Academy of Sciences

 

Commentary on Twitter

 

PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.

11 Aug, 2021 | 08:52h | UTC

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Invited Commentary: The use of inhaled corticosteroids in early-stage COVID-19

 

M-A: More than 50 long-term effects of COVID-19.

11 Aug, 2021 | 08:47h | UTC

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Related:

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

 

Commentary on Twitter

https://twitter.com/svillapol/status/1425032774793285648

 

BaSICS RCT: Among critically ill patients requiring fluid therapy, there was no difference in mortality with slower (333 mL/h) vs. faster (999 mL/h) intravenous fluid bolus rates.

11 Aug, 2021 | 08:37h | UTC

Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Does Crystalloid Composition or Rate of Fluid Administration Make a Difference When Resuscitating Patients in the ICU? – JAMA (free for a limited period)

Video: Balanced Solution vs. Saline in Intensive Care Study

 

CDC Report: COVID-19 morbidity and mortality far exceed the potential risks of rare side effects caused by vaccines.

11 Aug, 2021 | 08:45h | UTC

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 – CDC Morbidity and Mortality Weekly Report

 

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

11 Aug, 2021 | 08:44h | UTC

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

Related:

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

https://twitter.com/JohnGRizk/status/1425126093288353800

 

BaSICS RCT: Among critically ill patients requiring fluid therapy, treatment with a balanced solution did not lead to reduced mortality compared to a 0.9% saline solution.

11 Aug, 2021 | 08:39h | UTC

Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill PatientsThe BaSICS Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Does Crystalloid Composition or Rate of Fluid Administration Make a Difference When Resuscitating Patients in the ICU? – JAMA (free for a limited period)

Video: Balanced Solution vs. Saline in Intensive Care Study

 

Commentary on Twitter

 

New WHO toolkit promotes inclusion of people with dementia in society.

11 Aug, 2021 | 08:31h | UTC

New WHO toolkit promotes inclusion of people with dementia in society – World Health Organization

See Guidance: Towards a dementia inclusive society: WHO toolkit for dementia-friendly initiatives (DFIs) – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

RCT: Triaging acute pulmonary embolism for home treatment by Hestia vs. simplified PESI criteria – the tools were similarly effective, and more than a third of patients were treated at home with a low incidence of complications.

11 Aug, 2021 | 08:27h | UTC

Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial – European Heart Journal

 

Commentary on Twitter

 

M-A: Child and youth mental health problems have doubled during COVID-19.

10 Aug, 2021 | 10:03h | UTC

Commentary: Child and youth mental health problems have doubled during COVID-19 – The Conversation

Original study: Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis – JAMA Pediatrics

Editorial: Addressing the Global Crisis of Child and Adolescent Mental Health – JAMA Pediatrics

Related:

More data on the harmful effects of the COVID-19 pandemic on the mental health of adolescents.

COVID has caused ‘mass trauma,’ worsening mental health globally.

COVID’s mental-health toll: how scientists are tracking a surge in depression

CDC Report: Mental health-related emergency department visits among children aged under 18 years raised during the COVID-19 Pandemic

WHO: COVID-19 disrupting mental health services in most countries

 

Commentary on Twitter (thread – click for more)

 

Systematic review: Prescribing practices, patterns, and potential harms in patients receiving palliative care – “many patients receiving palliative care receive multiple medications closer to the time of death”.

11 Aug, 2021 | 08:23h | UTC

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

 

Commentary on Twitter

 

[Preprint] Phase 1/2 RCT: A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac.

10 Aug, 2021 | 09:58h | UTC

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – medRxiv

 

Commentary on Twitter

https://twitter.com/hildabast/status/1424644994120372224

 

A WHO expert explains why she believes the rush for Covid-19 boosters is premature.

10 Aug, 2021 | 09:56h | UTC

A WHO expert explains why she believes the rush for Covid-19 boosters is premature – STAT

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.